Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
  • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
  • C12N9/6424—Serine endopeptidases (3.4.21)
  • C12N9/6456—Plasminogen activators
  • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
  • C12Y304/21—Serine endopeptidases (3.4.21)
  • C12Y304/21069—Protein C activated (3.4.21.69)

Definitions

• the present invention is directed to a method of purifying recombinant proteins from related host cell proteins.
• the invention is also directed to the monoclonal antibodies used in the purification, and to an assay for the related host cell protein.
• t-PA human tissue plasminogen activator
• CHO Chinese hamster ovary
• t-PA Human t-PA is an extremely important new biological pharmaceutical agent shown to have great promise in the treatment of vascular diseases due to its high specificity and potent ability to dissolve blood clots in vivo. Accordingly, t-PA has been hailed by medical science as one of the most impressive new agents of recent history for the treatment of vascular occlusive disease, and in particular, heart disease. For these and other reasons, t-PA will likely revolutionize the clinical management of serious vascular disease.
• Monoclonal antibodies which bind to human t-PA but do not bind to swine t-PA have been made, for example European Patent Application 190711 relates to monoclonal antibodies which are specific to human tissue plasminogen activator obtained from a tissue cultured liquor of normal human tissue derived cells. Use of these monoclonal antibodies in the purification of human t-PA and in an assay for human t-PA, are disclosed. Monoclonal antibodies X-21 and X-23 did not cross react with urokinase or plasminogen activator extracted from swine heart.
• European Patent Application 210870 discloses an affinity reagent containing an immobilized Kunitz inhibitor which is produced in the seeds of Erythrina latissima and other Erythrina plants.
• the affinity reagent is said to be capable of separating human cell derived t-PA and host cell derived plasminogen activator from each other.
• Verheijen et al., EMBO Journal, Vol. 5, No. 13, pp 3525-3530 (1986) disclose the presence of CHO-PA when expressing human t-PA in CHO cells.
• the subject invention relates to a method for purifying a recombinant protein from a corresponding endogenous protein of the host cell comprising the steps of contacting fluid containing recombinant protein with antibodies specifically binding the corresponding endogenous protein, and recovering said recombinant protein.
• the invention also relates to an assay for the corresponding endogenous protein and to the monoclonal antibodies specifically binding the corresponding endogenous protein.
• recombinant proteins can be isolated from related host cell proteins by immunopurification using monoclonal antibodies.
• the invention relates to a method wherein fluid obtained from culturing a host cell expressing a recombinant protein as well as the corresponding endogenous proteins of the host cell is contacted with antibodies specifically binding the corresponding endogenous protein.
• the monoclonal antibodies bind the corresponding endogenous protein and the human recombinant protein is then recovered.
• t-PA tissue plasminogen activator
• CHO Chinese hamster ovary
• the subject invention provides a method wherein fluid obtained from culturing CHO cells expressing human t-PA as well as Chinese hamster plasminogen activator (PA) is contacted with antibodies, advantageously monoclonal antibodies, which bind Chinese hamster PA.
• the human t-PA is not bound and a separation is effected.
• the subject invention also relates to monoclonal antibodies specific for Chinese hamster PA, and to an assay for detecting the presence of Chinese hamster PA.
• the method of the subject invention is preferable to the use of antibodies specifically binding human t-PA, since the latter method requires purification means, e.g. a column, several orders of magnitude larger than the method of the subject invention since the concentration of human t-PA is several orders of magnitude larger than the concentration of CHO-PA.
• purification means e.g. a column
• concentration of human t-PA is several orders of magnitude larger than the concentration of CHO-PA.
• human tissue plasminogen activator As used herein, the terms "human tissue plasminogen activator”, “human t-PA” or “t-PA” denotes human extrinsic (tissue type) plasminogen activator, produced, for example, from natural source extraction and purification (see Collen et al., supra.), and by recombinant cell culture systems as described herein. Its sequence and characteristics are set forth, for example, in European Patent Application Publication No. 93619, (published 9 November 1983) based upon a first filing on 5 May 1982, incorporated herein by reference. See also European Patent Application Publication No. 41766 (published 16 Dec. 1981) based upon a first filing of 11 Jun. 1980 and Rijken et al., Journal of Biol. Chem.
• Human t-PA can be produced by transfecting a variety of eukaryotic cells, such as baby hamster kidney cells, myeloma cells, insect cells, 3T3 cells, and other transfectable cells having a useful post-transfectional life.
• eukaryotic cells such as baby hamster kidney cells, myeloma cells, insect cells, 3T3 cells, and other transfectable cells having a useful post-transfectional life.
• CHO Chinese hamster ovary
• monoclonal antibodies specifically binding CHO-PA were isolated from continuous hybrid cell lines formed by the fusion of antigen-primed immune lymphocytes with myeloma cells.
• polyclonal antibodies specifically binding CHO-PA are used.
• Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional antibody (polyclonal) preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. Monoclonal antibodies are useful to improve the selectivity and specificity of diagnostic and analytical assay methods using antigen-antibody binding. A second advantage of monoclonal antibodies is that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins. Monoclonal antibodies may be prepared from supernatants of cultured hybridoma cells or from ascites induced by intra-peritoneal inoculation of hybridoma cells into mice.
• mice as the test model although it is contemplated that any mammalian subject including human subjects or antibody producing cells therefrom can be manipulated according to the processes of this invention to serve as the basis for production of mammalian, including human, hybrid cell lines.
• immune lymphoid cells are fused with myeloma cells to generate a hybrid cell line which can be cultivated and subcultivated indefinitely, to produce large quantities of monoclonal antibodies.
• the immune lymphoid cells selected for fusion are lymphocytes and their normal differentiated progeny, taken either from lymph node tissue or spleen tissue from immunized animals. Applicants prefer to employ immune spleen cells, since they offer a more concentrated and convenient source of antibody producing cells with respect to the mouse system.
• the myeloma cells provide the basis for continuous propagation of the fused hybrid.
• Myeloma cells are tumor cells derived from plasma cells.
• the source of immunized antibody producing cells and myeloma be from the same species.
• the hybrid cell lines can be maintained in culture in vitro in cell culture media.
• the cell lines of this invention can be selected and/or maintained substantially indefinitely in a composition comprising the continuous cell line in the known hypoxanthine-aminopterin-thymidine (HAT) medium.
• HAT hypoxanthine-aminopterin-thymidine
• the hybrid cell lines can be stored and preserved in any number of conventional ways, including freezing and storage under liquid nitrogen.
• Frozen cell lines can be revived and cultured indefinitely with resumed synthesis and secretion of monoclonal antibody.
• the secreted antibody is recovered from tissue culture supernatant by conventional methods such as precipitation, ion exchange, affinity chromatography, or the like.
• EBV immortalized B cells are used to produce the monoclonal antibodies of the subject invention.
• Other methods for producing monoclonal antibodies such as recombinant DNA, are also contemplated.
• the processes of this invention comprise incubating or otherwise contacting the sample to be tested with monoclonal antibodies and detecting the presence of a reaction product.
• monoclonal antibodies are appropriately labeled.
• a convenient label for this assay is a radioactive isotope, particularly 125 I.
• enzymes particularly peroxidase are also useful.
• the antibody is labeled with a radioactive element, an enzyme or a fluorescent material.
• the radiolabel can be detected by any of the currently available counting procedures.
• the preferred isotope labels are 14 C, 131 I, 125 I, 3 H and 35 S.
• the enzyme label can be detected by any of the currently utilized colorimetric, spectrophotometric, fluorospectro-photometric or gasometric techniques.
• the enzyme is combined with the antibody with bridging molecules such as carbodiimides, periodate, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized.
• Examples are peroxidase, alkaline phosphatase, ⁇ -glucuronidase, ⁇ -D-glucosidase, ⁇ -D-galactosidase, urease, glucose oxidase plus peroxidase, galactose oxidase plus peroxidase and acid phosphatase.
• Fluorescent materials which may be used include, for example, fluorescein, rhodamine and auramine.
• Various labeling techniques are described in Morrison, Methods in Enzymology 32b, 103 (1974), Syvanen et al., J. Biol. Chem. 284, 3762 (1973) and Bolton and Hunter, Biochem J. 133, 529(1973) hereby incorporated by reference.
• a female Balb/c mouse was immunized over a period of 12 weeks with protein solutions substantially enriched in Chinese hamster plasminogen activator purified from host cell lacking the human t-PA geneo There were five injections each consisting of approximately 30 ⁇ g. The initial injection was emulsified with complete Freund's adjuvant and administered in one subcutaneous site(s). The second injection given 1.5 weeks later was emulsified with incomplete Freund's adjuvant and half was administered subcutaneously and half intraperitoneally. The remaining three injections were given on weeks 3, 6 and 12 in phosphate buffered saline (PBS) administered in one intraperitoneal site.
• PBS phosphate buffered saline
• the spleen from the immunized mouse was removed on week 13 and spleen cells were fused with the mouse myeloma cell line NP3X63-Ag8.653 using the general procedures of S. Fazekas, de St. Groth and D. Scheidegger (J. Immunol. Methods 35, 1 (1980)) and Lane, R. D. (J. Immunol. Methods 81 223 (1985)).
• the fused cells were distributed into ten microtiter plates each containing 96 wells. Each well was screened for specific antibody production using differential reactivity in two ELISA's (enzyme linked immunoadsorbant assays).
• One ELISA specifically detected antibodies against CHO-PA and the second detected antibodies that cross-reacted with recombinant human tissue plasminogen activator (t-PA).
• CHO-PA specific ELISA 50 ng/mL of CHO-PA in 50 mM carbonate buffer pH 9.6 was adsorbed to microtiter wells overnight at 4° C. The antigen was removed and the wells were washed with phosphate buffered saline containing 0.05% Tween 20 (PBS-TW20). Further adsorption was inhibited by adding 1% gelatin in Tris buffered saline (TBS; 0.15M NaCl, 0.05M Tris pH 7.4) to the wells and incubating for 1 h at room temperature.
• TBS Tris buffered saline
• the human t-PA specific ELISA differed from the CHO-PA specific ELISA in the first step. 200 ng/mL of t-PA in 50 mM carbonate buffer at pH 9.6 was adsorbed to microtiter wells overnight at 4° C. The remainder of the ELISA was identical.
• Hybridoma cells from wells containing CHO-PA specific antibodies were expanded and cloned by limiting dilution (Oi, V.T. and Herzenberg, L. A. 1980. Immunoglobin-Producing Hybrid Cell Lines p. 351-372, in Selected Methods in Cellular Immunology, Mishell, B.B. and Shiigi, S.M. (eds.) W. H. Freeman and Co.). Large quantities of specific monoclonal antibodies were produced by cell culture of the hybridoma cells or by injection of hybridoma cells in mice thereby producing ascites tumors.
• the subject invention also relates to a monoclonal antibody based assay for the quantitation of Chinese hamster ovary cell plasminogen activator (CHO-PA).
• Immunoassays using specific monoclonal antibodies provide one approach to the quantitation of small amounts of such a protein impurity which exists in the presence of a vast excess of the biochemically related recombinant product.
• An ELISA that specifically detects CHO-PA and not human t-PA was developed using two CHO-PA specific monoclonal antibodies (MAb) designated 335 and 361.
• MAbs were selected based on their capacity to bind 125 I-labeled CHO-PA, their minimal cross-reactivity with human t-PA and the fact that they each bound to a different epitope on CHO-PA. These antibodies demonstrated positive reactivity with CHO-PA, but did not react with human t-PA which had been depleted of CHO-PA. The capacity of each MAb to bind CHO-PA was assessed by determining the amount of 125 I-labeled CHO-PA that bound to each MAb that was non-specifically adsorbed to microtiter wells.
• the 125 I-labeled CHO-PA was pre-incubated with one MAb in solution before adding the mixture to the microtiter well containing the second MAb. If the first MAb did not inhibit the 125 I-labeled CHO-PA from binding to the second MAb, they were considered to be against different epitopes.
• the cross-reactivity of the MAbs with human t-PA was assessed by ELISA. 100 ng of either CHO-PA or t-PA was adsorbed to microtiter wells. Various dilutions of the purified MAbs were reacted with each antigen and the amount of antibody bound was determined using a horseradish peroxidase conjugated goat anti-mouse antibody. The cross-reactivity was calculated from the dilutions that resulted in the same absorbance against CHO-PA and human t-PA for a given MAb.
• CHO-PA specific "sandwich" ELISA was developed using MAb 335 to coat microtiter Wells and MAb 361 was conjugated to horseradish peroxidase to detect bound CHO-PA.
• the assay standard is cloned CHO-PA which was expressed in CHO cells.
• the assay is accurate, precise, and specific for the detection and quantitation of CHO-PA.
• the sensitivity (limit of detection) of this ELISA is about 3.9 ng/mL of CHO-PA and the cross-reactivity with human t-PA is less than about 0.002 percent.
• human t-PA containing CHO-PA was passed over a column of sepharose 4B coupled with monoclonal antibody 341 which is specific for CHO-PA.
• the material which flowed through this column represented human t-PA which had been depleted of CHO-PA and therefore was an appropriate sample for the determination of assay specificity.
• Antibody 341 is directed to a different antigenic determinant on CHO-PA than either antibody 335 or 361.
• purification of human t-PA by this antibody avoids purification and subsequent measurement of CHO-PA by the same antibody (i.e., directed to the same antigenic determinant).
• Table 1 demonstrates the assay values obtained for the immunoaffinity purification of CHO-PA from human t-PA using this antibody.
• recombinant CHO-PA was spiked into a sample of rt-PA which had been depleted of endogenous CHO-PA by immunoaffinity chromatography.
• Spike recovery analysis of CHO-PA added independently at concentrations of 11.5 and 31.5 ng/mL demonstrated mean recoveries of 103 and 105 percent respectively.
• MAb 354 affinity columns can be re-used many times to remove CHO-PA from recombinant human t-PA harvest fluids without significant losses in binding activity.
• a MAb 354 column is suitable for use as a reusable biospecific filter for removal of trace levels of CHO-PA from human t-PA as shown below.
• ELISA based elution studies were also performed. Analysis of the elution behavior for the various MAbs was evaluated with respect to several buffers including pH 3.0 and pH 2.0 acetic acid containing low (0.15M) and high (1.5M) NaCl; sodium thiocyanate 3M, pH 8.5, pH 10.0; 2M sodium thiocyanate pH 8.5 and pH 5.2; 2.0M MgCl 2 , pH 5.2; and glycine pH 5.2 (all potential affinity column eluants).
• the monoclonal antibodies showed different patterns or sensitivity to these reagents. For example, 354 and 361 were easily removed from plate coated CHO-PA under acid conditions and 359 and 361 were resistant to 3M NaSCN, pH 8.5 buffer. The 354 MAb was removed by a broad spectrum of eluants.
• t-PA harvest fluid Twenty ml of t-PA harvest fluid was loaded onto each column, and each was washed with 30 column volumes of PBS. The t-PA harvest fluid flow through was assayed for CHO-PA after chromatography. The various affinity columns were ranked on the basis of the amount of CHO-PA remaining in the flow through (Table 3). In a control experiment t-PA harvest fluid was applied to an ethanolamine blocked Sepharose CL 4 B column containing no antibody. As shown below the MAb 354 was superior with respect to CHO-PA removal. It is also important to note that the acetic acid eluants from each column were analyzed by SDS gel analysis and compared to t-PA harvest fluid and purified recombinant CHO-PA standards. Eluted protein obtained from most of the affinity columns co-migrated with the recombinant CHO-PA standard, indicating that the MAbs tested were highly selective for CHO-PA trace contaminant and were not cross-reactive with human t-PA.
• MAb 354 was immobilized to CNBr activated Sepharose CL 4B and used in affinity column experiments to purify recombinant CHO-PA from cell culture fluids.
• MAb 354 appeared to be stable for multiple purification cycles where NaSCN 2M, pH 8.5 and pH 3.0 glycine was employed for CHO-PA elution and column regeneration.
• Mab 354 was immobilized on Sepharose 6 Fast Flow which had been activated by carbonyl diimidazole by the method of Bethell et al. (J. Biol. Chem. 254 (8), pp 2572-2574, 1979). This resin was used to remove CHO-PA from partially purified preparations of human t-PA. Levels of CHO-PA were reduced by at least 100 fold and the resin showed no change in function over at least 60 cycles in which 3M NaSCN, pH 8, was used as a regenerant.
• MAb 354 was immobilized to N-hydroxysuccinimide activated AffiPrep resin from BioRad and was tested at 4° C. for ability to remove CHO-PA derived from t-PA harvest fluid.
• the reuse capability of the 354 affinity column was also tested.
• Monoclonal antibody was coupled at 3 mg/ml of resin.
• Column flow rate was fixed at 20 column volumes per hour. The column was loaded with 25 column volumes of unconcentrated t-PA harvest fluid, washed with 20 column volumes of PBS buffer, regenerated with 5 column volumes of 2.0M Guanidine HCL, in 0.2M acetic acid pH 3.0 and then reequillibrated with 10 column volumes of PBS.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• General Health & Medical Sciences (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• General Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Enzymes And Modification Thereof (AREA)

Priority Applications (6)

Applications Claiming Priority (1)

Publications (1)

Family

ID=22374375

Family Applications (1)

Country Status (6)

Cited By (3)

Families Citing this family (1)

Citations (3)

Family Cites Families (1)

• 1987
  • 1987-11-05 US US07/117,705 patent/US5411864A/en not_active Expired - Lifetime
• 1988
  • 1988-11-02 WO PCT/US1988/003900 patent/WO1989004367A1/en active IP Right Grant
  • 1988-11-02 AT AT89900037T patent/ATE134218T1/de not_active IP Right Cessation
  • 1988-11-02 DE DE3855007T patent/DE3855007T2/de not_active Expired - Lifetime
  • 1988-11-02 EP EP89900037A patent/EP0389538B1/en not_active Expired - Lifetime
  • 1988-11-02 JP JP1500175A patent/JP2756162B2/ja not_active Expired - Lifetime

Patent Citations (3)

Non-Patent Citations (9)

Also Published As

Similar Documents

Legal Events